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AbstrAct:
Background: Glioblastoma (GBM) is a malignant brain tumor with dismal 
prognosis. GBM patients have a median survival of less than 2 years. 
GBM  is  characterized  by  fast  cell  proliferation,  infiltrative  migration, 
and by the induction of angiogenesis. MicroRNAs and polycomb group 
(PcG) proteins have emerged as important regulators of gene expression. 
Methods:  Here we determined that miR-101 is down-regulated in GBM, 
resulting in overexpression of the miR-101 target PcG protein EZH2, a histone 
methyltransferase  affecting  gene  expression  profiles  in  an  epigenetic  manner. 
Results:  Inhibition of EZH2 in vitro by pre-miR-101, EZH2 siRNA, or 
small molecule DZNep, attenuated GBM cell growth, migration/invasion, 
and GBM-induced endothelial tubule formation. In addition, for each 
biological  process  we  identified  ontology-associated  transcripts  that 
significantly  correlate  with  EZH2  expression.  Inhibition  of  EZH2 in 
vivo  by systemic DZNep administration in a U87-Fluc-mCherry GBM 
xenograft mouse imaging model resulted in reduced tumor growth. 
Conclusion: Our results indicate that EZH2 has a versatile function in GBM 
progression and that its overexpression is at least partly due to decreased 
miR-101 expression. Inhibition of EZH2 may be a potential therapeutic 
strategy to target GBM proliferation, migration, and angiogenesis. 
IntroductIon
GBM remains among the most devastating cancers 
with a median survival of less than 15 months and virtually 
no survival beyond five years [1]. GBM is the grade IV 
glioma and can arise de novo or through progression of 
lower  grade  gliomas.  Evidence  supporting  the  critical 
role of proliferation, migration and angiogenesis in the Oncotarget 2010; 1:  710 - 720 711 www.impactjournals.com/oncotarget
biological behavior of these tumors has led to a variety of 
studies on the basic mechanisms involved. GBM cells are 
highly proliferative but are also notorious because of their 
capacity to migrate through the brain parenchyma and 
their ability to induce angiogenic blood vessel sprouting. 
Several factors are involved in the angiogenesis process, 
which results in recruitment, proliferation and alignment 
of endothelial blood vessel cells through a complex 
interaction between endothelial cells and tumor cells [2]. 
miRNAs comprise a large group of endogenous 
non-coding RNAs that can block mRNA translation or 
negatively regulate mRNA stability and thereby play a 
central role in the regulation of gene expression [3]. It is 
also becoming clear that deregulated miRNA expression 
is a common feature of human diseases, especially 
in  specific  forms  of  cancer  [4,5].  Recent  studies  have 
identified several miRNAs that are altered in GBM tumor 
cells  themselves  [6,7]  as  well  as  in  GBM-associated 
endothelial cells [8]. 
PcG proteins are important epigenetic regulators 
which can function as transcriptional repressors that silence 
specific  sets  of  genes  through  chromatin  modification 
[9].  PcG  proteins  are  grouped  in  polycomb  repressive 
complexes  (PRC).  PRC2  includes  enhancer  of  zeste  2 
(EZH2), suppressor of zeste 12 (SUZ12), and embryonic 
ectoderm development (EED). EZH2 is the catalytically 
active component of PRC2 and is capable of trimethylating 
lysine 27 of histone H3 (H3K27) when in complex with 
SUZ12 and EED [10-15]. Recently, an increasing number 
of studies linked various oncogenic properties to EZH2, 
including impaired cellular differentiation and enhanced 
proliferation and in vivo  tumor  growth  [16-22].  EZH2 
is overexpressed in various cancers, which correlates to 
decreased  patient  survival  [16,18,19,23-25].  Although 
EZH2 knock down was shown to be embryonic lethal in 
mice [26], knock down of EZH2 in cancer cells resulted 
in growth arrest, as well as in diminished tumor growth 
and reduced metastasis in vivo [16,20,22]. The role of 
Figure 1: EZH2 expression is associated with high grade glioblastoma. (A) Representative tissue sections stained with an antibody 
directed against EZH2. Immunohistochemical staining shows absent nuclear staining of non-neoplastic brain (NNB), and strong nuclear staining 
in glioblastoma (GBM). Scale bar = 100 µm. (B) Quantification of EZH2 protein expression in glioma tissue microarrays. Negative = 0%; 
Weak = <5%; Intermediate 5-25%; Strong = >25% positive EZH2 staining. EZH2 expression correlates to glioma grade (left) and to glioma 
recurrence (right). (C) Correlation between GBM patient survival and EZH2 mRNA expression, red indicates high EZH2 expression, yellow 
indicates low EZH2 expression and blue indicates all patients (http://caintegrator-info.nci.nih.gov/rembrandt). (D) EZH2 protein analysis by 
Western blot on various cell lines and non-neoplastic brain tissue (NNB).
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PcG proteins in GBM is not well understood, but has 
been described to involve bone morphogenetic protein 
signaling, controlling the differentiation capacity of GBM 
cells [27].
Here  we  report  that  EZH2  expression  in  GBM 
is  regulated  by  miR-101.  We  show  that  miR-101  is 
down-regulated in GBM cells, resulting in increased 
EZH2 expression and enhanced GBM cell proliferation, 
migration, and angiogenesis. 
rEsults
To evaluate the expression levels of EZH2 in GBM 
cells and non-neoplastic brain (NNB) we performed 
immunohistochemistry for EZH2 protein expression on 
tissue microarrays containing GBM and NNB samples. 
Most of the GBM samples showed fields of strong nuclear 
staining for EZH2 while none of the NNB samples did 
(Fig.  1A).  Increased  EZH2  expression  correlated  with 
glioma grade and glioma recurrence (Fig. 1B), suggesting 
that EZH2 could be a marker for glioma aggressiveness. 
In addition, the Rembrandt database was used to show that 
EZH2 expression correlated with decreased GBM patient 
survival (Fig. 1C). EZH2 protein was strongly expressed 
in human GBM cell lines, including U251 and U87, but 
not in NNB (Fig. 1D).
In  order  to  determine  whether  potential  GBM-
expressed  miRNAs  could  affect  EZH2  expression  we 
first determined which miRNAs expressed in NNB are 
differentially  expressed  in  GBM  (Supplemental  Table 
S1A). Next, we used miRbase [28] to identify 63 miRNAs 
predicted to target EZH2. Upon integration of the list of 
miRNAs  predicted  to  target  EZH2  and  the  differential 
GBM/NNB miRNA expression ratios, we found that 
miR-101, miR-98, miR-137, and miR-139 were down-
regulated in GBM tissue as compared to NNB and have 
Figure 2: mir-101 is down-regulated in GbM and targets EZH2. (A) Predicted RNA structure of the 3’UTR of EZH2 by RNAfold 
software, in red the 2 miR-101 biniding sites are indicated. (B and C) Down-regulation of miR-101 was confirmed by qRT-PCR analysis. RNA 
extracted from surgically removed gliomas from patients was analyzed by qRT-PCR. The data were normalized to the level of GAPDH mRNA 
in each sample. NB = Non-neoplastic brain; II, III, IV indicate WHO glioma grades. (D) EZH2 and H3K27me3 expression analysis by Western 
blot in U87 GBM cells following transfection with pre-miR-101, pre-miR-control, EZH2 siRNA or control, or treatment with DZNep. Data 
presented as relative EZH2 expression compared to non-transfected (n.t.) cells. Error bars indicate s.d. *p<0.05, ***p<0.001, t test.  
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the potential to regulate EZH2 (Supplemental Table S1B). 
Another miRNA which was previously found to target 
EZH2, miR-26a [29], was not included in our subset of 
miRNAs expressed in the brain, and therefore not part of 
our study. 
We  were  particularly  interested  in  miR-101  since 
it was confirmed to bind the EZH2 3’-UTR at two sites 
(Fig. 2A), and was recently shown to interact with EZH2 
in other types of cancer [30,31]. Previous analysis showed 
that genomic loss of miR-101-1 and miR-101-2 alleles was 
observed in 18.7% of GBM cases [30,32]. Based on these 
findings, we decided to further analyze miR-101/EZH2 
functionality in GBM. First, down-regulation of miR-101 
was  confirmed  in  primary  glioma  samples  of  different 
WHO grades by quantitive PCR (qRT-PCR) analysis (Fig. 
2B and 2C). To establish that miR-101 affects EZH2 protein 
expression and histone methyltransferase activity in GBM, 
we transfected human U87 GBM cells with pre-miR-101 
molecules  and  determined  the  levels  of  EZH2  protein 
and H3K27me3. In addition to pre-miR-101, we included 
EZH2 siRNA, non-related control oligonucleotides, and 
the S-adenosylhomocysteine hydrolase inhibitor DZNep, 
a potent EZH2 inhibitor [33,34]. DZNep, EZH2 siRNA, 
and  pre-miR-101  all  notably  repressed  EZH2  protein 
expression and reduced the levels of trimethylation of 
H3K27 (Fig. 2D), indicating inhibition of EZH2 function. 
To  determine  the  effects  of  EZH2  on  GBM  cell 
proliferation  we  first  analyzed  which  genes  associated 
with cell proliferation correlated with EZH2 expression in 
GBM and NNB [35]. First, EZH2 was found overexpressed 
in most GBM samples as compared to NNB. However, in 
few samples the EZH2 mRNA expression was found to be 
in the same range as in the NNB (Fig. 3A). Out of the 1419 
genes that were linked to the proliferation gene ontology 
as  determined  by  AmiGO  [36],  214  genes  showed  a 
clear correlation (>67%) with EZH2 expression in GBM 
(Fig. 3A). Interestingly, the GBM samples with normal 
EZH2  expression  levels  also  showed  less  expression 
of  the  genes  associated  with  cell  proliferation.  Next, 
cellular proliferation was studied in GBM cell cultures to 
determine if EZH2 influences the proliferation of GBM 
cells. miR-101 induction, EZH2 knock down by siRNA 
and treatment with DZNep significantly reduced cellular 
proliferation in U87-GFP GBM cells (Fig. 3B and 3C). 
The effect of DZNep treatment on proliferation inhibition 
was confirmed in other GBM cell lines in vitro (Fig. 3D). 
To  determine  the  effects  of  EZH2  on  GBM  cell 
migration  we  analyzed  which  genes  belonging  to  the 
migration gene ontology correlated with EZH2 expression 
Figure 3: mir-101-regulated EZH2 affects GbM proliferation in vitro. (A) In silico analysis of EZH2 mRNA expression and the 
correlation to proliferation-related mRNAs. Heatmap of percentile fold change of gene expression of proliferation-related genes sorted by 
correlation with EZH2 expression (rows) in patients sorted by level of EZH2 expression (columns). (B) Fluorescence microscopical images of 
U87-GFP cells 96 h after inhibition of EZH2 by transfection with miR-101 precursor, EZH2 siRNA or treatment with DZNep. Scale bar = 450 
µm. (C) U87-GFP cells were treated as in (B) and cell proliferation was measured by WST-1 proliferation assay. (D) A panel of human GBM 
cell lines, (U87, U118, U251 and U373) and a rat GBM cell line (C6) were treated with 5 µM DZNep. Proliferation compared to untreated 
control was measured by cell counts in a casy count apparatus. Human breast cancer cell line MCF-7 was included as a positive control. Error 
bars indicate s.d. *p<0.05, ***p<0.001, t test.   
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Figure 4: In silico analysis of EZH2 mrnA expression and the 
correlation to migration-related mrnAs. Heatmap of percentile fold 
change of gene expression of migration-related genes sorted by correlation 
with EZH2 expression (rows) in patients sorted by level of EZH2 expression 
(columns). Color coding is similar to Fig 3A. (B) U87 monolayer cultures 
were scratched. Images were acquired directly after scratching (t = 0) and 
24 h later (t = 24). The migration front is indicated by the dashed lines. 
Scale bar = 450 µm. (C) Quantitation of cell migration into the scratch using 
ImageJ software. (E and F) U87 cells were transfected with pre-miR-101, 
EZH2 siRNA, non-related control molecules, or treated with DZNep, and 
analyzed for invasion capability. EZH2 inhibition decreased invasion as 
shown by Hoechst staining. Error bars indicate s.d. *p<0.05, ***p<0.001, t 
test. Scale bar = 225 µm.Oncotarget 2010; 1:  710 - 720 715 www.impactjournals.com/oncotarget
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in GBM and NNB. A significant correlation between the 
expression of 28 out of 279 genes associated with cell 
migration and EZH2 expression was observed (Fig. 4A). 
In  order  to  determine  whether  miR-101  up-regulation 
or  EZH2  inhibition  also  affected  GBM  cell  migration, 
scratch  assays  were  performed.  Up-regulation  of  miR-
101 by pre-miR-101 resulted in a significant decrease in 
U87 migration. The EZH2 inhibitors DZNep and EZH2 
siRNA showed a similar decrease in migration (Fig. 4B 
and 4C). To further evaluate the effects of miR-101/EZH2 
modulation on in vitro migration and invasion, a Boyden 
chamber assay was used. U87 cells that were transfected 
with pre-miR-101 showed a significant decrease in ability 
to invade, as visualized by Hoechst staining (Fig. 4D and 
quantitated in 4E). Again, similar results were observed 
after treatment with the EZH2 inhibitor DZNep or EZH2 
knock down by siRNA (Fig. 4D and 4E). 
To determine the effects of EZH2 on GBM-induced 
angiogenesis  we  also  analyzed  which  genes  belonging 
to the angiogenesis gene ontology correlated with EZH2 
expression  in  GBM.  Again,  a  significant  correlation 
between the expression of 33 out of 308 genes associated 
with  angiogenesis  and  EZH2  expression  was  observed 
(Fig.  5A).  Next,  HBMVECs  were  cultured  in  EBM, 
EGM, or EBM supplemented with U87 human GBM cells 
expressing GFP (U87-GFP), all on a Matrigel substratum 
to  promote  tubule  network  formation.  Tubules  were 
visualized  by  a  combination  of  light  and  fluorescence 
microscopy. After pre-treatment of the GBM cells with 
DZNep, or transfection with pre-miR-101, EZH2 siRNA, 
or non-related oligonucleotides of similar chemistry, and 
subsequent  co-culturing  with  HBMVECs  on  Matrigel, 
we  analyzed  tubule  length  and  tubule  branching.  Up-
regulation  of  miR-101  in  U87-GFP  cells  resulted  in  a 
substantial decrease in total tubule length and tubule 
branching (Fig. 5B and 5C). In addition to pre-miR-101, 
treatment of the U87-GFP cells with EZH2 siRNA and 
DZNep  also  inhibited  U87-induced  tubule  network 
formation (Fig. 5B and 5C).
Finally, to study the effects of modulation of EZH2 
on GBM growth in vivo,  we  implanted  U87  human 
GBM  cells  stably  expressing  Fluc  and  the  fluorescent 
protein mCherry (U87-Fluc-mCherry) into the flanks of 
nude mice. Tumor growth was monitored over time by 
intravenous injection of the Fluc substrate D-luciferin and 
in vivo bioluminescence imaging using a CCD camera. 
Figure 5: mir-101/EZH2 affects GbM angiogenesis in vitro. (A) In silico 
analysis  of  EZH2  mRNA  expression  and  the  correlation  to  angiogenesis-related 
mRNAs.  Heatmap  of  percentile  fold  change  of  gene  expression  of  angiogenesis-
related genes sorted by correlation with EZH2 expression (rows) in patients sorted 
by level of EZH2 expression (columns). Color coding is similar to Fig 3A. (B) U87-
Fluc-mCherry cells were treated and co-cultured with HBMVECs on Matrigel coated 
plates. Tubule formation was assessed 96 h after transfection as tubule length and 
branching. Scale bar = 450 µm. (C) Quantitation of tubule length and branching in (B) 
using ImageJ software. Error bars indicate s.d. *p<0.05, ***p<0.001, t test.Oncotarget 2010; 1:  710 - 720 716 www.impactjournals.com/oncotarget
After tumor cell implantation, we injected one set of mice 
(n = 5) intravenously with the EZH2 inhibitor DZNep 
(0.07 mg/kg) and a parallel control set (n = 5) with PBS 
only, at day 3, 5, and 7, followed by weekly injection. 
CCD camera imaging of Fluc bioluminescence activity in 
the tumor allowed us to monitor tumor growth over time. 
The tumor volume of the mice treated with PBS increased 
logarithmically over time, while the tumor volume in the 
mice treated with DZNep showed reduced growth (Fig. 
6A and 6B). 
dIscussIon
Here  we  show  that  miR-101  is  down-regulated 
in  glioma  in  a  grade  dependent  manner. The  impaired 
translational repression of EZH2 by miR-101 causes EZH2 
overexpression in GBM, which correlates with patient 
survival.  EZH2  is  a  methyltransferase  that  affects  the 
expression of many genes. Based on in silico expression 
analysis  and  EZH2  expression  correlation  we  found 
that EZH2 overexpression induces glioma proliferation, 
migration/invasion, and angiogenesis, processes driving 
glioma progression.
miR-101/EZH2  was  found  to  be  deregulated  in 
several other types of cancer, including prostate cancer 
[30],  bladder  transitional  cell  carcinoma  [31],  gastric 
cancer  [37],  and  described  to  strongly  correlate  with 
migration,  invasion,  and  metastasis  [30,37].  Here  we 
demonstrate  a  role  for  EZH2  overexpression  in  GBM, 
which  could  be  inhibited  by  miR-101,  siEZH2,  or 
small  molecule  inhibitor  DZNep.  Besides  induction  of 
migration and invasion, we identified a role for EZH2 in 
cellular proliferation and the induction of angiogenesis, 
indicating a versatile pro-tumoral function for EZH2 in 
GBM. Inhibition of EZH2 by DZNep resulted in reduced 
GBM growth in vitro and in a limited experiment in vivo. 
Altogether,  these  results  indicate  that  EZH2  may  be  a 
useful drug target for the treatment of GBM.
miRNAs are know to affect cellular processes 
such as angiogenesis [8,38,39]. Here we show a role for 
miR-101  in  GBM-induced  angiogenesis.  Unpublished 
data  indicate  that  miR-101  also  regulates  EZH2  in 
endothelial  cells.  We  provide  evidence  that  miR-101 
down-regulation regulates angiogenesis by induction of 
EZH2 and a pro-angiogenic mRNA profile. However, the 
exact mechanisms of EZH2 function in endothelial and 
GBM cells remains to be investigated. Besides miR-101, 
we  also  found  the  predicted  EZH2  targeting  miRNAs 
miR-98, miR-137, and miR-139 to be down-regulated in 
GBM cells as compared to NNB tissue. It remains to be 
Figure 6: Inhibition of EZH2 affects GbM development in vivo. (A) 1 x 106 U87-Fluc-mCherry cells were implanted s.c. in nude 
mice. Tumor growth was monitored by in vivo Fluc bioluminescence imaging. After implantation, one set of mice was injected i.v. with DZNep 
and another set with PBS, at day 3, 5 and 7, followed by weekly injection. (B) Quantitation of Fluc.
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investigated whether these miRNAs truly repress EZH2, 
and whether other previously identified miR-101 target 
genes are also repressed by miR-101 in GBM cells, these 
may include Cox-2, Mcl-1 and Fos [37], MAGI-2 [40], 
DNA-PKcs  and ATM  [41],  COX-2  [42]. The  complex 
interaction  of  reduced  miR-101-mediated  translational 
repression and increased EZH2-mediated transcriptional 
repression at least seem to cause pro-tumoral switches 
in  the  GBM  transcriptome  profile.  Interestingly,  our 
results  also  identified  that  a  subset  of  GBMs  express 
normal levels of EZH2 mRNA. We found that the genes 
associated with proliferation, migration, and angiogenesis 
were also expressed in the normal range, following the 
EZH2 expression levels. Further research in the nature 
and behavior of this subset of EZH2-low GBMs and its 
correlation to miR-101 expression is warranted.
In conclusion, our results indicate that EZH2 has 
a versatile pro-tumoral function in GBM and that its 
overexpression is at least partly due to decreased miR-
101 expression. Inhibition of EZH2 may be a potential 
therapeutic strategy to target GBM proliferation, 
migration, and angiogenesis.
MAtErIAls And MEtHods
cells
Human  brain  microvascular  endothelial  cells 
(HBMVECs; Cell Systems ACBRI-376) were cultured in 
EGM medium (Lonza). C6, 293T, MCF-7, U118, U251, 
U373, and U87 cells (U-87 MG; ATCC) were cultured 
in DMEM (Lonza) containing 10% FBS and antibiotics. 
U87-Fluc-mCherry  cells  were  produced  by  stably 
transducing U87 cells with CMV-controlled expression 
cassette using a lentiviral vector [43].
Quantitive rt-Pcr 
Quantitive RT-PCR (qRT-PCR) analysis was used 
to determine the relative expression levels of miR-101, 
miR-186, EZH2, and GAPDH mRNA. Total RNA was 
isolated using the miRVANA miRNA isolation kit. Equal 
amounts of RNA were converted into cDNA using miR-
101, miR-186, EZH2, and GAPDH RT primers (Applied 
Biosystems and Qiagen, according to the manufacturer’s 
protocol). Subsequently, quantitive PCR was performed 
using primers and materials from Applied Biosystems. All 
experiments were performed using biological triplicates 
and experimental duplicates. The data was normalized to 
miR-186 or GAPDH expression levels. 
disclosed primers used were: 
human EZH2 (forward)/ (reverse)
5’-CCTGAAGTATGTCGGCATCGAAAGAG-3’ 
5’-TGCAAAAATTCACTGGTACAAAACACT-3’ 
human GAPDH (forward)/ (reverse)
5’-GTCGGAGTCAACGGATT-3’
5’-AAGCTTCCCGTTCTCAG-3’
2.3 Western blots and immunohistochemistry. 
EZH2  protein  and  H3K27me3  expression  was 
detected  by  SDS-PAGE  followed  by  Western  blot 
analysis,  using  mouse  anti-EZH2  monoclonal  antibody 
(BD  biosciences)  and  rabbit  anti-H3K27me3  (Upstate 
Biotechnology). Mouse anti-Actin (Millipore) was used 
as a loading control. Protein levels were detected using 
ECL detection solution (GE healthcare) and visualized on 
X-ray film (GE healthcare). Paraffin sections of human 
GBM tissue and NNB were incubated with monoclonal 
mouse anti-EZH2 (BD biosciences) antibodies. Positive 
reactions were visualised using a secondary antibody 
(DAKO  EnvisionHRP)  and  3,3-diaminobenzidine  or 
liquid red chromogen. 
mirnA modulation 
50 nM of pre-miR-101 (Ambion) or pre-miR-control 
(Ambion)  oligonucleotides  were  transfected  into  U87 
human GBM cells using Lipofectamin2000 (Invitrogen), 
according the manufacturer’s protocol. For the inhibition 
of EZH2 50 nM of EZH2 siRNA (Qiagen) was transfected 
into  U87  cells.  siRNA-AF  or  control  oligonucleotides 
(Qiagen) were used as controls. After 5 h of transfection, 
the transfection medium was replaced by DMEM until 
further analysis. 
In silico analysis
A RNA microarray dataset containing 81 GBM and 
23 NNB samples as published by [35] was used to obtain 
mRNA expression estimates. To quantify the differential 
level of expression for each glioblastoma sample, the 
significance  analysis  of  microarrays  algorithm  was 
performed using the samr package (version 1.24 by B. 
Narasimhan  and  R.  Tibshirani)  in  R, A  Language  and 
Environment  for  Statistical  Computing  (release  2.4.1; 
Vienna,  Austria;  http://www.R-project.org)  based  on 
randomization. Unpaired two class comparison for cancer 
versus normal tissue samples was performed, unless paired 
samples were involved, in which case a paired analysis Oncotarget 2010; 1:  710 - 720 718 www.impactjournals.com/oncotarget
was performed. The selection of the delta parameter was 
based on a median false discovery rate less than 0.05. 
The default number of 100 permutations was used. This 
resulted in fold change values for all 19769 genes on the 
Affymetrix microarray platform. Using the AmiGO tool 
[36] of the Gene Ontology project [44] lists of transcripts 
associated with the biological processes proliferation 
(GO:0008283;  9/20/10),  migration  (GO:0030334; 
9/20/10) and angiogenesis (GO:0001525; 9/20/10) were 
obtained.  Lists  of  unique  transcripts  were  prepared  by 
removing duplicate entries. Subsequently the microarray 
dataset  was  queried  for  the  genes  in  each  of  these 
ontologies.  Samples  were  sorted  on  EZH2  expression 
level for the NNB and GBM samples separately and the 
average expression levels scaled on a gene by gene basis 
for genes significantly correlating with EZH2 expression 
(absolute value Pearson correlation > 0.667) were plotted 
as a heatmap using the gplots package in R. 
In vitro angiogenesis assay 
HBMVECs  were  cultured  on  Matrigel  (BD 
biosciences) in EBM (Lonza) in the presence or absence 
of  U87-Fluc-mCherry  cells,  or  EGM  (Lonza).  The 
experiments were performed in triplicate, repeated twice 
and judged in a double blind fashion by at least two 
observers. At  least  3  pictures  were  taken  randomly  of 
each culture well using a digital camera system (Leica). 
Total tubule length and number of branches were analyzed 
using the software program ImageJ. 
In vitro migration assay 
GBM cells were grown to confluence in 24-wells 
plates and were transfected with 50 nM of oligonucleotides 
or treated with DZNep (5 µM). At 72 h after transfection 
an artificial wound was created using a pipette tip after 
which the cells were further incubated. To analyse cell 
migration into the scratched area, pictures were taken at 
0 and 24 h using a digital camera system coupled to a 
microscope. ImageJ was used to determine the migration 
distance (in μm) as the reduction of the width of the open 
area.
In vitro invasion assay 
GBM invasion function was analyzed using a Boyden 
chamber assay. A 24-well Transwell system (Corning) was 
used, with each well containing a permeable transwell 
insert  containing  a  6.5  mm  polycarbonate  membrane 
with 8 μm pores. The inserts were coated with 4x diluted 
basement  membrane  extract  (Trevigen)  and  incubated 
overnight in 5% CO2 at 37ºC. GBM cells were transfected 
with 50 nM of oligonucleotides for 24 h or treated with 
DZNep (5 µM for 24 h), starved for 24 h and harvested 
in serum free medium. Per insert 25,000 GBM cells were 
subsequently placed on the membrane. The inserts were 
immersed in a 24-well plate that was filled with EGM 
growth medium culture media. After incubation for 24 h, 
the membrane was washed briefly with PBS. The upper 
side of the membrane was then wiped gently with a cotton 
ball. The membrane was then fixed in 4% formaldehyde 
and stained with Hoechst. The magnitude of GBM cell 
migration was evaluated by counting the migrated cells in 
3 random high-power (5x) microscope fields. 
tumor model and bioluminescence imaging
All animal studies were approved by the 
Massachusetts General Hospital Review Board. Nude mice 
were anesthetised with i.p. injection of xylazine (5 mg/kg) 
and ketamine (100 mg/kg). 50 µl containing 1 x 106 U87-
Fluc-mCherry cells were pre-mixed with an equal volume 
of matrigel (BD biosciences) and implanted in the flanks 
of nude mice. DZNep was administered intravenously to 
tumor-bearing mice at a dose of 0.07 mg/kg diluted in 100 
µl PBS at day 3, 5 and 7 after tumor implantation, followed 
by weekly injection. Mice were anesthetized as above and 
Fluc  imaging  was  performed  10  min  after  intravenous 
injection  of  150  µl  beetle  D-luciferin  (4  mg/kg  body 
weight) (Xenogen), and recording photon counts over 5 
min using a cooled CCD camera with no illumination. 
Dim polychromatic illumination was used to take a light 
image of the animal. Visualization was performed using 
CMIR-Image,  a  program  developed  by  the  Center  for 
Molecular  Imaging  Research  using  image  display  and 
analysis suite developed in IDL (Research Systems Inc., 
Boulder, CO). An intensity contour procedure to identify 
bioluminescence  signals  with  intensities  significantly 
greater than the background was used to define regions of 
interest. The mean, standard deviation and sum of photon 
counts in these regions were calculated as a measurement 
of Fluc activity.
statistics
Difference  in  biological  properties  between 
parental  and  EZH2  downregulated  cells  was  analysed 
using  Student’s  t-test.  P-values  <0.05  were  considered 
statistically significant. 
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